Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a large increase in short interest in February. As of February 15th, there was short interest totalling 2,520,000 shares, an increase of 43.2% from the January 31st total of 1,760,000 shares. Based on an average daily volume of 6,070,000 shares, the short-interest ratio is presently 0.4 days. Approximately 6.9% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in Cardio Diagnostics by 97.6% in the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock worth $334,000 after buying an additional 179,978 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Cardio Diagnostics during the 4th quarter valued at about $236,000. Jane Street Group LLC bought a new stake in shares of Cardio Diagnostics in the fourth quarter worth approximately $103,000. Finally, Two Sigma Securities LLC purchased a new position in shares of Cardio Diagnostics during the fourth quarter valued at approximately $48,000. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Trading Down 0.5 %

Shares of NASDAQ CDIO traded down $0.00 during midday trading on Tuesday, hitting $0.42. The stock had a trading volume of 860,517 shares, compared to its average volume of 3,036,152. The business’s 50 day moving average is $0.62 and its 200-day moving average is $0.47. Cardio Diagnostics has a 52 week low of $0.19 and a 52 week high of $1.77.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.